Recombinant HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017] (ab198557)
![Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017] (ab198557)](https://www.abcam.com/ps/products/198/ab198557/Images/ab198557-255265-IHCAP22575281.jpg "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017] (ab198557)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- HRP Rabbit monoclonal [EPR2017] to Retinoic Acid Receptor beta
- Suitable for: WB, IHC-P
- Reacts with: Human
- Conjugation: HRP
Overview
-
Product name
HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017]
See all Retinoic Acid Receptor beta primary antibodies -
Description
HRP Rabbit monoclonal [EPR2017] to Retinoic Acid Receptor beta -
Host species
Rabbit -
Conjugation
HRP -
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human Retinoic Acid Receptor beta aa 400 to the C-terminus.
-
Positive control
- WB: MCF7, Daudi and U-87 MG whole cell lysates. IHC-P: FFPE human normal kidney tissue sections.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark. -
Dissociation constant (KD)
KD = 1.13 x 10 -11 M Learn more about KD -
Storage buffer
pH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: 30% Glycerol, 1% BSA, PBS -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR2017 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
-
Positive Controls
-
Recombinant Protein
-
Related Products
Applications
Our Abpromise guarantee covers the use of ab198557 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | 1/5000. Detects a band of approximately 55 kDa (predicted molecular weight: 50 kDa). | |
| IHC-P | 1/50. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Target
-
Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to corepressors. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function. -
Involvement in disease
Microphthalmia, syndromic, 12 -
Sequence similarities
Belongs to the nuclear hormone receptor family. NR1 subfamily.
Contains 1 nuclear receptor DNA-binding domain. -
Domain
Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain. -
Cellular localization
Cytoplasm and Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 5915 Human
- Omim: 180220 Human
- SwissProt: P10826 Human
- Unigene: 543218 Human
- Unigene: 581530 Human
- Unigene: 654490 Human
- Unigene: 733004 Human
-
Alternative names
- HAP antibody
- HBV-activated protein antibody
- NR1B2 antibody
see all
Images
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017] (ab198557)
IHC image of Retinoic Acid Receptor beta staining in a section of formalin-fixed paraffin-embedded human normal kidney*. The section was pre-treated using pressure cooker heat mediated antigen retrieval with sodium citrate buffer (pH6) for 30mins, and incubated overnight at +4°C with ab198557 at 1/50 dilution. DAB was used as the chromogen (ab103723), diluted 1/100 and incubated for 10min at room temperature. The section was counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
-
![Western blot - HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017] (ab198557)](https://www.abcam.com/ps/products/198/ab198557/Images/ab198557-242585-WBab1985571.jpg)
Western blot - HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017] (ab198557)All lanes : HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017] (ab198557) at 1/5000 dilution
Lane 1 : MCF-7 (Human breast adenocarcinoma cell line) Whole Cell Lysate
Lane 2 : Daudi (Human Burkitt's lymphoma cell line) Whole Cell Lysate
Lane 3 : U-87 MG (Human glioblastoma astrocytoma) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 50 kDa
Observed band size: 55 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutesThis blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab198557 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
-
![HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017] (ab198557)](https://www.abcam.com/ps/products/198/ab198557/Images/ab198557-3-benefits-of-recombinant-antibodies.png)
HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017] (ab198557)
Protocols
References (1)
ab198557 has been referenced in 1 publication.
- Ren HY et al. Upregulation of retinoic acid receptor-ß reverses drug resistance in cholangiocarcinoma cells by enhancing susceptibility to apoptosis. Mol Med Rep 14:3602-8 (2016). PubMed: 27599527
